Haleon PLC Completes Share Buyback Transaction

Haleon PLC Sponsored ADR ( (HLN) ) has shared an update.

On April 30, 2025, Haleon PLC announced the completion of a share buyback transaction, purchasing 858,187 ordinary shares on April 29, 2025, as part of its previously announced buyback program. This transaction is part of Haleon’s strategy to manage its capital structure and provide value to its shareholders, potentially impacting the company’s market positioning by reducing the number of shares with voting rights to 9,017,767,343.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.

Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company’s product portfolio includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Haleon is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are built on a foundation of science, innovation, and understanding of human needs.

YTD Price Performance: 8.48%

Average Trading Volume: 11,581,487

Technical Sentiment Signal: Sell

Current Market Cap: $45.59B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.